Effects of Pazopanib on Liver Cancer Growth
Author Information
Author(s): Zhu Xiao-Dong, Zhang Ju-Bo, Fan Pei-Li, Xiong Yu-Quan, Zhuang Peng-Yuan, Zhang Wei, Xu Hua-Xiang, Gao Dong-Mei, Kong Ling-Qun, Wang Lu, Wu Wei-Zhong, Tang Zhao-You, Ding Hong, Sun Hui-Chuan
Primary Institution: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China
Hypothesis
Pazopanib has antiangiogenic effects that can inhibit tumor growth in hepatocellular carcinoma models.
Conclusion
Pazopanib effectively inhibits tumor growth in hepatocellular carcinoma xenografts through its antiangiogenic effects, which can be evaluated using quantitative contrast-enhanced ultrasonography.
Supporting Evidence
- Pazopanib significantly inhibited tumor growth in HCCLM3, HepG2, and PLC/PRF/5 xenograft models.
- Mean transit time of contrast media in tumors was inversely correlated with intratumoral microvessel density.
- Pazopanib induced apoptosis and inhibited migration and invasion in liver cancer cell lines.
Takeaway
Pazopanib is a medicine that helps stop liver cancer from growing by blocking the blood vessels that feed the tumor.
Methodology
The study evaluated the effects of pazopanib on human liver cancer cell lines and in three xenograft mouse models, using contrast-enhanced ultrasonography to assess tumor perfusion.
Limitations
The study did not test other dosages or schedules of pazopanib and was limited to subcutaneous tumor models.
Participant Demographics
Male BALB/c nu/nu mice, aged 4-6 weeks.
Statistical Information
P-Value
0.037
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website